Second-Generation Antiandrogen Therapy Radiosensitizes Prostate Cancer Regardless of Castration State through Inhibition of DNA Double Strand Break Repair

SIMPLE SUMMARY: The combination of RT and the first generation AR blockers to improve the outcome in prostate cancer remain a matter of controversial debate in clinical trials. In the current study we aim to investigate the effect of three FDA approved second-generation antiandrogens (abiraterone ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsesy, Mohamed E., Oh-Hohenhorst, Su Jung, Löser, Anastassia, Oing, Christoph, Mutiara, Sally, Köcher, Sabrina, Meien, Stefanie, Zielinski, Alexandra, Burdak-Rothkamm, Susanne, Tilki, Derya, Huland, Hartwig, Schwarz, Rudolf, Petersen, Cordula, Bokemeyer, Carsten, Rothkamm, Kai, Mansour, Wael Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563746/
https://www.ncbi.nlm.nih.gov/pubmed/32878283
http://dx.doi.org/10.3390/cancers12092467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563746/
https://www.ncbi.nlm.nih.gov/pubmed/32878283
http://dx.doi.org/10.3390/cancers12092467

Ejemplares similares